skip to Main Content

In Vitro Antiviral Testing

Well-characterized assays for a growing selection of viruses   Now Available! VSV-SARS-CoV2 Neutralization Assay

In Vitro Antiviral Testing

Assays for a wide selection of gram-positive and gram-negative bacteria

reagents

Now Available!  New Reagents for S. aureus research.  Multiple antigen/antibody combinations.

Now Available!   Human IgG ELISA Kit

Animal Models

Antiviral & antibacterial disease models – Immunogenicity testing, Pharmacokinetics & toxicity

Assay & Protein Services

Custom development, analysis and expression services

About IBT

The IBT Bioservices mission is to provide top client value by applying our infectious disease expertise, collaborative scientific interaction, and a flexible, cost-effective business model. The result is timely and relevant data for our clients’ needs.

Our scientists are leaders in their areas and can provide the highest level of expertise for your R&D programs. Read more about IBT.

Spotlight On:

Back To Top
Search
Fig. 1 Survival after challenge with INFV H1N1 A/Pert/261/2009 (Tamiflu-resistant strain). Inoculum 1xLD90=1.0E+05 PFU/mouse
Survival after challenge with INFV H1N1 A/Pert/261/2009 (Tamiflu-resistant strain) 1.0E+05 PFU/mouse
Survival and weight change in BALB/c mice challenged with INFV A/ Texas/36/91 (H1N1) and treated with antiviral Osletamivir Phosphate (Tamiflu)
Lung viral load and Survival (30 % weight loss cut-off) in BALB/c mice challenged with INFV H3N2 A/HK/1/68.